Radiprodil

Phase 3Small molecule

Radiprodil is one of 102 small molecule programs targeting GRIN-related Neurodevelopmental Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase 1Recruiting

ChildrenActive, not recruiting

SeizureRecruiting

Recruiting

Phase 1Phase 1

Recruiting

ChildrenPhase 1

Active, not recruiting

SeizurePhase 2

Recruiting

Competition

Competitive Landscape

59 competitors in Phase 1

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

4 2

Fludara

Sanofi

Phase 2

4 3

Venclexta

AbbVie

Phase 2

2 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

5 5

Erbitux

IImclone

Phase 2

3 6

Rayos

RRoxane Laboratories

Phase 2

1 7

Radiprodil

GGRIN Therapeutics, Inc.

Phase 3

1 8

Navitoclax

AbbVie

Phase 2

1 9

Yervoy

Bristol-Myers Squibb

Phase 1

1 10

Benznidazole

CCorestemchemon, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Children

NCT05818943

Q3 2027

Phase 1Recruiting

Phase 1

NCT07457229

Q3 2028

Phase 3Recruiting

GRIN-Related Neurodevelopmental Disorder

NCT07224581

Clinical

Trials by Indication[1]

Children1 trial

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

Active, not recruiting·GGRIN Therapeutics, Inc.·Phase 1·NCT05818943·24 enrolled

Infantile Spasms1 trial

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

Terminated· UCB logo

UCB·Phase 2·NCT02829827·3 enrolled

Seizure1 trial

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

Recruiting·GGRIN Therapeutics, Inc.·Phase 1/2·NCT06392009·30 enrolled

Phase 11 trial

Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants

Recruiting·GGRIN Therapeutics, Inc.·Phase 1·NCT07457229·40 enrolled

Interaction1 trial

Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.

Completed·GGRIN Therapeutics, Inc.·Phase 1·NCT06975605·18 enrolled

3 more indications

Adult1 trial

Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults

Terminated·GGRIN Therapeutics, Inc.·Phase 1·NCT06965881·30 enrolled

Oral1 trial

Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers

Completed· UCB logo

UCB·Phase 1·NCT02647697·10 enrolled

GRIN-related Neurodevelopmental Disorder1 trial

A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

Recruiting·GGRIN Therapeutics, Inc.·Phase 3·NCT07224581·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Radiprodil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radiprodil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radiprodil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GRIN Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGRIN Therapeutics, Inc.

Radiprodil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q3 2028

Trials by Indication[1]

Children1 trial

Infantile Spasms1 trial

Seizure1 trial

Phase 11 trial

Interaction1 trial

Adult1 trial

Oral1 trial

GRIN-related Neurodevelopmental Disorder1 trial

References

Drug Info

Quick Facts

Related News